(Q38737251)

English

Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events

scientific article published on 03 February 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Subvisible Particle Content, Formulation, and Dose of an Erythropoietin Peptide Mimetic Product Are Associated With Severe Adverse Postmarketing Events (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1 reference

based on heuristic

inferred from title

Dean D. Metcalfe

12

object named as

Dean D Metcalfe

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

author name string

Joseph Kotarek

1

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Christine Stuart

2

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Silvia H De Paoli

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Jan Simak

4

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Tsai-Lien Lin

5

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yamei Gao

6

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Mikhail Ovanesov

7

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yideng Liang

8

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Dorothy Scott

9

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Janice Brown

10

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Yun Bai

11

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Ewa Marszal

13

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Jack A Ragheb

14

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

language of work or name

0 references

publication date

3 February 2016

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Journal of Pharmaceutical Sciences

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

105

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

1023-1027

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Increased potency of an erythropoietin peptide mimetic through covalent dimerization

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Anaphylaxis and hypotension after administration of peginesatide

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Flow imaging microscopy for protein particle analysis--a comparative evaluation of four different analytical instruments

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

A critical review of analytical methods for subvisible and visible particles

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Critical evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein aggregates

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

A double antigen bridging immunogenicity ELISA for the detection of antibodies to polyethylene glycol polymers

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Concurrent inhibition of kit- and FcepsilonRI-mediated signaling: coordinated suppression of mast cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

IgG-dependent activation of human mast cells following up-regulation of FcgammaRI by IFN-gamma

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3549%2815%2900180-X

7 January 2021

Identifiers

10.1016/S0022-3549(15)00180-X

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38737251&oldid=2133468276"